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INTRODUCTION
Cancer remains one of the leading causes of death
worldwide. In Pakistan, like other parts of the world,
breast cancer is the most common malignancy in
women followed by oral cavity and ovarian cancer.1,2 In
addition, the number of breast cancer cases is on the
rise, for instance in 2004, Karachi Cancer Registry has
reported 69.1% ASR per 100,000 from 1998 to 2000 in
comparison to 53% per 100,000 during 1995 to 1997.1
Bhurgri et al. also reported an association of family
history in 10% of the early onset (less than 45 years)
breast cancer patients in Pakistan.3
Both BRCA1 and BRCA2 genes are important to familial
breast cancer and reportedly confer 80% life time risk of
breast cancer and 40% life time risk of ovarian cancer.4
Mutations in BRCA1 and BRCA2 genes have been
reported worldwide, but the type of mutations differ
considerably from country to country. Rashid et al.
studied 176 Pakistani breast cancer patients and
reported thirty germ-line mutations.5 Most of the studies
in familial breast cancer patients were carried out in
large pedigree families with multiple affected relatives
over many generations; the parameters of such studies
cannot be applied to interpret small pedigree families.6-8
Likewise, breast cancer patients with moderate family
history have not been studied in the Pakistani
population.
The aim of the present study was to determine BRCA1
mutations in early onset cancer patients (age < 45
years) from Pakistan with and without moderate family
history.
METHODOLOGY
Overall, 53 breast cancer patients confirmed on the
basis of clinical and laboratory diagnosis were recruited
from the Oncology Clinics of the Aga Khan University
Hospital, Karachi, between May 2005 and December
2009. The criteria for inclusion were based on the
involvement of first degree and/or second degree
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relatives with breast and/or ovarian cancer and age at
the time of diagnosis. The participants (breast cancer
patients) were divided into three groups; (a) women with
early onset (< 38 years) breast cancer without first
degree relatives with breast cancer, (b) women with
breast cancer under the age of 45 years with at least
one first or second degree relative with breast cancer,
(c) women with bilateral breast cancer having first
degree relative with breast or ovarian cancer. Out of
53 patients, 23 did not report family history but
demonstrated early onset breast cancer and their ages
ranged between 20 and 37 years. On the other hand,
remaining 30 patients exhibited moderate family history.
Peripheral blood samples were collected from patients
in 5 ml tubes containing EDTA as anti-coagulant. This
study was approved by the institution's ethical review
committee. 
DNA was extracted from the blood samples by Wizard
DNA extraction kit (Promega, Madison, WI, USA),
according to the manufacturer’s instructions. It was
diluted to 100 ng/µl concentration in molecular biology
grade deionized water. PCR assay for BRCA1 exons 2,
5, 6, 20 and 22 was carried out according to the
published protocols. The amplified products were
verified on agarose gel and analyzed by SSCP assay
that was performed for the screening of BRCA1
mutations as described by Futreal et al.9 Briefly, 10 µl of
PCR product was mixed with 10 µl of gel loading dye
(95% formamide, 10 mM NaOH, 0.05% bromophenol
blue and xylene cyanol) and was applied to 0.5 x MDE
gel (FMC Bioproducts, USA). After electrophoresis at
room temperature in 0.6 x TBE, the gel was silver
stained and photographed. Exon 11 of BRCA1 was
analyzed by PTT assay according to Hogevorst
protocol.10 It was amplified as three overlapping
fragments with 5' primers modified to carry a T7
promoter site. Amplicons were used as template for
in vitro transcription and translation for producing a 35S
methionine labelled protein. Protein products were
separated on a 10% polyacrylamide gel, fixed and
autoradiographed. DNA samples revealing sequence
variations by SSCP or PTT assay were confirmed by
cycle sequencing (CEQ 8000, Beckman, USA).
Statistical analysis was carried out using Statistical
Package for Social Sciences (SPSS) version 19.0 for
windows. Fisher's exact test was used to observe the
association of degree of relationship (first and second),
other cancer history, age at menarche, menopausal
status and age at first child birth with the family history
group. Age at onset was found non-normally distributed,
while age at menopause was found to be normally
distributed using Kolmogorov-Smirnov and Shapiro Wilk
methods. Kruskal Wallis test was used to compare age
at onset by family history group. Results were
considered significant for p < 0.05.
RESULTS
Fifty three patients recruited on the basis of early onset
breast cancer were screened for mutations in BRCA1
exons by PTT and SSCP techniques. Mobility shift was
identified in exons 6, 16 and 20 of the BRCA1 gene in
three patients. Figure 1 (a-f) shows a representative gel
electrophoresis patterns of 3 positive patients for
mutations in exons 6, 16, and 20. These exons were
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Table I: Distribution of sequence variants in BRCA1 exons.
Patient ID Age BRCA1 exon Nucleotide Amino acid Reported in Mutation type1 Ethnicity Family Other cancer
change change BIC history history 
3 28 11 c.1123T > G stop at 374 Novel FM Pashtun Pos Neg
19 29 20 c.5231delG ORF Novel FM Mohajir Pos Neg
30 39 16 c.4837A > G S1613G Reported PM Mohajir Pos Neg
48 48 6 c.271T > G C91W Novel MS Mohajir Pos Neg
1FM= frame shift mutation; PM= polymorphism; MS = missense mutation.
Table II: Comparison of risk factors among BRCA1 negative familial,
BRCA1 mutation carrier and non-familial (< 45 years old) breast
cancer patients.
Variable Family history group p-value
Famiial Non-familial BRCA1
(n=26) (n=23) (n=4) 
Age at onset1 41.0 33.0 35.5 0.018
(34.8, 49.2) (30.0, 35.0) (28.2, 42.8)
First degree relation
Yes 23 (88.5%) 0 3 (75%) < 0.001
No 3 (11.5%) 23 (100%) 1 (25%)
Second degree relation
Yes 7 (26.9%) 0 1 (25%) 0.017
No 19 (73.1%) 23 (23%) 3 (75%)
Other cancer history
Yes 19 (73%) 21 (91.3%) 3 (75%) 0.300
No 6 (23%) 2 (8.7%) 1 (25%)
Age at menarche2
< 12 2 (7.7%) 3 (13%) 0 0.309
12 14 (53.8%) 6 (26.1%) 1 (25%)
> 12 9 (34.6%) 13 (56.%) 2 (50%)
Menopause status
Yes 5 (19.2%) 4 (17.4%) 0 1.000
No 21 (80.8%) 19 (82.6%) 4 (100%)
Age at first child birth
< 30 years 16 (61.5%) 13 (56.5%) 2 (50%) 0.159
> 30 years 1 (3.8%) _ _
No birth _ 6 (26.1%) 1 (25%)
Unknown 9 (34.6%) 4 (17.47%) 1 (25%)
1Median (inter-quartile range);    2 n=50 (3 observations are missing)
further amplified and sequenced to confirm the location
of mutations. As shown in Table I, BRCA1 mutation was
identified in exon 11 in a Pathan patient, while mutations
in exon 6, 16, 20 were identified in Urdu speaking
(Mohajir) families. Figure 1 illustrates the sequence
analysis of exons 6, 16, and 20. Except for a
polymorphism identified in exon 16 (c.4837 A > G), the
other two mutations in exon 6 (c.271 T > G) and 20
(c.5231 del G) were novel mutations. Exon 11 of BRCA1
gene was screened for missense mutations using PTT
assay. As presented in Table I, in one subject a
nucleotide exchange (T > G) at position c.1123 was
confirmed, which resulted in conversion of amino acid
Leucine at position 374 to stop codon.
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Figure 1 (a-f): Single strand conformation polymorphism (SSCP) assay for germ-line mutation in exons 6, 16, 20 (a, b, c) differential migration pattern of patient
sample marked by arrow on SSCP gel conformed by direct sequencing (d) a germ-line mutation in the BRCA1 (exon 6). A missense substitution at c.271 G > T.
(e) mutation in the BRCA1 (exon16). A missense substitution at c.4837G > A. (f) a germ-line mutation in the BRCA1 (exon 20). One bp deletion in BRCA1 at
c.5231 del G is marked by an arrow.
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Table II shows the distribution of breast cancer patients
by family history group. The first group consisted of 26
familial breast cancer patients; their median age at time
of diagnosis was 41 years. In this group, 43.3% cases
acquired the disease after 40 years of age and a large
proportion of their second degree relatives (37%) were
diagnosed for breast cancer at less than 38 years of
age. The median age of the onset of breast cancer in
BRCA1 positive (35.5 years) and non-familial breast
cancer patients (33 years) was comparatively lower than
the familial group (41 years) and it was statistically
significant (p=0.018). In addition, comparison of risk
factors among the patient groups illustrated in Table II
shows more first and degree relatives affected by the
disease in BRCA1 mutation carriers and non-carriers
familial patients (first degree relatives, p = < 0.001).
Although, family members 3/4 BRCA1 positive patients
reported malignancies other than breast cancer,
nevertheless, the difference was not statistically
significant (p=0.300). In addition, the difference in risk
factors such as age at menarche and menopause or
age at first child birth did not appear significant among
the groups or when compared with the Western
populations. Furthermore, uterine and ovarian cancers
were frequently reported in the family members of
BRCA1 positive patients.
DISCUSSION
In the last several decades, the issue of familial breast
cancer has received immense attention due to
advancements in early detection and treatment options
as well as discovery of breast cancer associated genes
e.g. BRCA1 and BRCA2. The data from earlier BRCA1
studies represented large pedigrees with multiple
affected relatives over several generations.
In the current study, pre-menopausal breast cancer
patients (less than 45 years) with moderate family
history were selected for the analysis of BRCA1 gene.
The exons of BRCA1 gene selected for analysis were 2,
5, 6, 11, 16, 20 and 22. Many published reports have
shown higher frequency of mutations in these exons.11-13
The frequency of BRCA1 mutations in our patients was
8%, which is in agreement with the mutation rate (6%)
reported by Yassaee et al. in the Iranian population.11
However, if patients with moderate family history are
included then the mutation rate would increase to 13%.
Many studies have shown BRCA1 mutation rate ranging
from 6-45%.14-17 The lower mutation rate in this study
highlights the importance for entire BRCA1 gene
analysis. Overall, four mutations were detected, three
were substitutions and one was deletion. Moreover,
except for one substitution at exon 16, all other
mutations were first time reported. A novel mutation
identified in exon 6 at position 271 results in cytosine to
tryptophan substitution at codon 91. This substitution
has the potential to disrupt formation of BRCA1/BARD1
heterodimers, which is an important step for retention of
BRCA1 in the nucleus for promoting DNA repair
process.18 In another patient, A > G substitution was
identified at position 1613 in exon 16, which was
reported in other populations as well, and according to
Breast Information Core (BIC) database, it is classified
as a polymorphism. Two mutations were detected in
exon 11 and 20. In exon 11, a single base substitution T
> G at position 1123 led to the creation of a stop codon
at amino acid position 375 leading to truncation of
BRCA1 protein. In addition, a frame shift mutation at
position 5231 was detected in exon 20. A linker region is
encoded by exon 20, which is positioned between N-
terminal and C-terminal BRCT regions of BRCA1 protein.19
The average age of patients carrying BRCA1 mutations
at the time of diagnosis was 36 years and 50% of the
patients were below 30 years, further confirming the fact
that BRCA1 mutations are associated with early onset
breast cancer. Several other studies have documented
a higher prevalence of BRCA1 mutations in patients
diagnosed at an early age.20 A meta-analysis of 22
breast cancer studies performed by Antoniou et al.
concluded that penetrance of mutated BRCA1 gene
depends upon index case's age, mutation site and
number of affected breast cancer relatives.21 In addition,
Al-Mulla et al. in 2008 published a study on penetrance
of BRCA1 and reported that different BRCA1 mutations
have different effect on the onset age of breast and
ovarian cancer.22
In the present study, BRCA1 mutations were not
detected in patients with early onset breast cancer
without family history and in a majority of patients with
moderate family history. These observations are
consistent with Peto et al. who also have demonstrated
lower penetrance of breast cancer genes in their
population.20 It is becoming evident that moderate
families which are characterized by less striking history
showed increased risk of disease. These families may
be affected by a mixture of low penetrance genes,
genetic factors and shared environmental factors.
This data was classified into two groups based on the
presence of BRCA1 mutations. The results suggested
that majority of BRCA1 mutation positive patients had
statistically significant (p < 0.001) involvement of first
degree relatives in comparison to second degree
relatives. These findings are also supported in previous
studies, which have shown strong association of family
history with disease and showed that the risk of disease
vary according to the nature of family history.23 On the
contrary, Kim et al. showed that most of their Korean
breast cancer patients with BRCA1 mutations did not
have a family history, which is in sharp contrast to the
well-known perception.24
Reproductive factors including early menarche, pre-
and postmenopause and age at first child birth were
evaluated in this study, but correlation with breast
cancer were inconsistent when compared with previously
BRCA1 status in breast cancer
reported studies. In addition, recently published studies
also failed to find a correlation between early menarche
and appearance of breast cancer at an early stage. Our
findings also demonstrated early menarche before 12
years of age in 3/23 of non-familial breast cancer
patients. Conversely, no case of early menarche was
observed in BRCA1 positive group. These findings are
consistent with studies that reported no correlation of
early menarche with the appearance of breast cancer in
early age.24,25
CONCLUSION
Familial breast cancer is a heterogeneous disease in
which hormonal, and environmental factors can
confound risks associated with BRCA1 mutations. We
found increased frequency of BRCA1 mutations in
breast cancer patients with moderate family history.
Pakistani patients can benefit from selective screening
of BRCA1 gene and mutation based counselling for small
and moderate families if one first or second degree
relative is affected or early onset disease is apparent.
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